Core Viewpoint - The article highlights five top stocks to consider for investment in early 2026, emphasizing their strong earnings potential and growth opportunities in various sectors. Group 1: Amazon - Amazon is positioned as a strong investment due to its leadership in e-commerce and cloud computing, with a market cap of $2.6 trillion and a gross margin of 50.05% [5][3] - The company is leveraging artificial intelligence to enhance its e-commerce efficiency and AWS has an annual revenue run rate exceeding $132 billion [5][3] - The stock is considered a safe bet with a current price of $240.95, reflecting a 3.38% increase [4][3] Group 2: Eli Lilly - Eli Lilly is a leader in the weight loss drug market, particularly with its products tirzepatide (Zepbound and Mounjaro), contributing to significant sales growth [6][8] - The company has a market cap of $1 trillion and a gross margin of 83.03%, with a current stock price of $1,064.04, up 2.16% [7][6] - The weight loss drug market is projected to reach nearly $100 billion by the end of the decade, indicating substantial growth potential for Lilly [9] Group 3: Chewy - Chewy operates in the pet e-commerce space, expanding into veterinary services, which broadens its revenue opportunities [10][12] - The company has achieved profitability and 84% of its sales come from its Autoship service, providing predictable revenue [12][11] - Chewy's current market cap is $13 billion, with a gross margin of 28.58% and a stock price of $32.16, reflecting a slight increase of 0.05% [11][10] Group 4: Apple - Apple has underperformed compared to the S&P 500 but is now focusing on AI features, which may attract investors looking for growth [14][15] - The company has a market cap of $3.9 trillion and a gross margin of 46.91%, with a current stock price of $262.36, down 1.83% [15][14] - Apple's services segment is a significant growth area, consistently reporting record revenues [16] Group 5: Moderna - Moderna is identified as a recovery story, facing challenges due to declining vaccine sales but has a promising pipeline of late-stage candidates [18][19] - The company aims to expand its seasonal vaccine offerings from three to six products by 2028 and is working towards cash breakeven [19][20] - Moderna has a market cap of $14 billion, a gross margin of 38.93%, and a current stock price of $35.66, reflecting a 10.85% increase [19][18]

Core Viewpoint - Moderna has transitioned from a clinical-stage biotech to a profitable commercial-stage company due to its coronavirus vaccine, but recent declines in vaccine sales and underperformance of its RSV vaccine raise concerns about its growth potential [1][2] Group 1: Moderna's Current Situation - Moderna's stock has seen a decline in vaccine sales, and its RSV vaccine has not met growth expectations [2] - Despite challenges, Moderna has made progress in cost-cutting and is focusing on promising programs, leading to a stock increase of over 30% in the past month [2] - The company aims for cash breakeven by 2028 and the launch of new products, which may not appeal to cautious investors [5] Group 2: Vertex Pharmaceuticals Overview - Vertex Pharmaceuticals is highlighted as a better investment option for both cautious and aggressive investors due to its strong earnings growth in cystic fibrosis treatment [6] - Vertex's CFTR modulators, Trikafta and Alyftrek, treat nearly 95% of cystic fibrosis patients, with ongoing development for remaining patients [7] - Vertex's revenue increased by 11% to over $3 billion in the latest quarter, driven by its CF products [8] Group 3: New Product Approvals and Pipeline - Vertex has expanded its product line with approvals for Casgevy and Journavx, which could significantly boost revenue in the coming years [9] - Journavx addresses a critical need for effective non-opioid pain management, with over 300,000 prescriptions filled since its launch [9] Group 4: Financial Performance and Valuation - Vertex's stock has increased nearly 100% over the past five years and about 15% this year, indicating strong long-term and short-term performance [11] - The current valuation of Vertex is 25 times forward earnings estimates, a reasonable price given its market leadership and expanding product portfolio [11] - Vertex's financial strength and diverse product offerings position it well for future growth, making it a more attractive investment compared to Moderna [12]

Core Viewpoint - Moderna has experienced significant stock price decline, down 80% over the past year, but has a promising late-stage pipeline that could lead to multiple product launches and revenue growth in the future [3][12]. Group 1: Company Performance - Moderna initially saw tremendous success with its coronavirus vaccine, generating billions in revenue and profit during the pandemic [2][5]. - The company has faced challenges as demand for the coronavirus vaccine has decreased, impacting earnings and stock performance [2][7]. - Despite recent approvals for updated vaccines and cost-cutting measures, Moderna's earnings trajectory remains difficult [3][10]. Group 2: Future Prospects - Moderna is preparing to launch up to 10 new products in the coming years, representing a total addressable market of $30 billion, which could significantly boost revenue [8]. - The company's pipeline includes a variety of programs across different indications, reducing reliance on any single product and mitigating risk [9]. - Moderna has made progress in cutting costs, with plans to reduce estimated GAAP operating costs by $1.7 billion by 2027 [10]. Group 3: Investment Considerations - The company has lost U.S. government funding for its investigational bird flu vaccine, and uncertainties regarding vaccine policies may pose challenges [11]. - Investors often perceive Moderna primarily as a COVID vaccine company, which may affect stock performance due to declining demand for that product [11]. - For investors willing to accept volatility and hold the stock for at least five years, Moderna presents an attractive investment opportunity given its potential for future revenue growth [12].